Psychiatry Research: Neuroimaging
Volume 173, Issue 3 , Pages 183-189 , 30 September 2009

Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [123I]IBZM SPECT

  • Gisela Johanna Elisabeth Schmitt

      Affiliations

    • Department of Psychiatry, Medical Center of the University of Munich, Munich, Germany
    • ,
  • Eva Maria Meisenzahl

      Affiliations

    • Department of Psychiatry, Medical Center of the University of Munich, Munich, Germany
    • Corresponding Author InformationCorresponding author. Nüssbaumstr. 7, 80336 Munich, Germany. Tel.: +49 89 5160 5772; fax: +49 89 5160 5708.
    • ,
  • Thomas Frodl

      Affiliations

    • Department of Psychiatry, Medical Center of the University of Munich, Munich, Germany
    • ,
  • Christian La Fougère

      Affiliations

    • Department of Nuclear Medicine, Medical Center of the University of Munich, Munich, Germany
    • ,
  • Klaus Hahn

      Affiliations

    • Department of Nuclear Medicine, Medical Center of the University of Munich, Munich, Germany
    • ,
  • Hans-Jürgen Möller

      Affiliations

    • Department of Psychiatry, Medical Center of the University of Munich, Munich, Germany
    • ,
  • Stefan Dresel

      Affiliations

    • Department of Nuclear Medicine, Medical Center of the University of Munich, Munich, Germany

Received 12 January 2006 ,Revised 17 October 2008 ,Accepted 3 November 2008.

References 

  1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. American Journal of Psychiatry. 1998;155:761–767
  2. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences. 2000;97:8104–8109
  3. Åsberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatrica Scandinavica. Supplementum. 1978;271:5–27
  4. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America. 1997;94:2569–2574
  5. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophrenia Research. 2006;85:232–244
  6. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica. 1963;20:140–144
  7. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annual Review of Pharmacology and Toxicology. 2001;41:237–260
  8. Copolov DL, Seal ML, Maruff P, Ulusoy R, Wong MTH, Tochon-Danguy HJ, et al. Cortical activation associated with the experience of auditory hallucinations and perception of human speech in schizophrenia: a PET correlation study. Psychiatry Research. Neuroimaging. 2003;122:139–152
  9. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;19:481–483
  10. Dresel S, Tatsch K, Dahne I, Mager T, Scherer J, Hahn K. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients. Journal of Nuclear Medicine. 1998;39:1138–1142
  11. Dresel S, Mager T, Rossmuller B, Meisenzahl E, Hahn K, Moller HJ, et al. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. European Journal of Nuclear Medicine. 1999;26:862–868
  12. Farde L, Wiesel F-A, Hall H, Halldin C, Stone-Elander S, Sedvall G. No D2 receptor increase in PET study of schizophrenia. Archives of General Psychiatry. 1987;44:671–672
  13. Farde L, Wiesel F-A, Stone-Elander S, Halldin C, Nordström A-L, Hall H, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]Raclopride. Archives of General Psychiatry. 1990;47:213–219
  14. Halligan PW, David AS. Cognitive neuropsychiatry: towards a scientific psychopathology. Nature Reviews. Neuroscience. 2001;2:209–215
  15. Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehikoinen P, Ruotsalainen U, et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Archives of General Psychiatry. 1994;51:116–123
  16. Hubl D, Koenig T, Strik W, Federspiel A, Kreis R, Boesch C, et al. Pathways that make voices. Archives of General Psychiatry. 2004;61:658–668
  17. Ichise M, Ballinger JR, Tanaka F, Moscovitch M, St. George-Hyslop PH, Raphael D, et al. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. Journal of Nuclear Medicine. 1998;39:1511–1518
  18. Johns LC, McGuire PK. Verbal self-monitoring and auditory hallucinations in schizophrenia. Lancet. 1999;353:469–470
  19. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276
  20. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. Journal of Cerebral Blood Flow and Metabolism. 2000;20:423–451
  21. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences. 1996;93:9235–9240
  22. Leysen JE, Van Gompel P, de Chaffoy de Courcelles D, Niemegeers CJ. Opposite regulation of serotonin-S2 and dopamine-D2 receptors in rat brain following chronic receptor blockade. Journal of Receptor Research. 1987;7:223–239
  23. McGuire PK, Silbersweig DA, Wright I, Murray RM, David AS, Frackowiak RS, et al. Abnormal monitoring of inner speech: a physiological basis for auditory hallucinations. Lancet. 1995;346:596–600
  24. McGuire PK, Silbersweig DA, Wright I, Murray RM, Frackowiak RS, Frith CD. The neural correlates of inner speech and auditory verbal imagery in schizophrenia: relationship to auditory verbal hallucinations. British Journal of Psychiatry. 1996;169:148–159
  25. Meisenzahl EM, Dresel S, Frodl T, Schmitt GJ, Preuss UW, Rossmuller B, et al. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. Journal of Psychopharmacology. 2000;14:364–370
  26. Möller HJ. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2003;27:1101–1111
  27. Mombour K, Kockott G, Fliege K. The use of the brief psychiatric rating scale (BPRS) by overall and gorham for the diagnosis of acute paranoid psychoses: evaluation of a German translation of the BPRS (author's transl). Pharmakopsychiatrie, Neuro-Psychopharmakologie. 1975;8:279–288
  28. Montgomery S, Åsberg M, Jornestedt L, Thoren P, Traskman L, McAuley R, et al. Reliability of the CPRS between the disciplines of psychiatry, general practice, nursing and psychology in depressed patients. Acta Psychiatrica Scandinavica. Supplementum. 1978;271:29–32
  29. Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, et al. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test–retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse. 2002;46:170–188
  30. Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kervin RW. Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone. British Journal Psychiatry. 1994;163:833–834(Erratum in: Br J Psychiatry 1994 Feb;164:270)
  31. Pohjalainen T, Rinne JO, Nagren K, Älahti ES, Hietala J. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. American Journal of Psychiatry. 1998;155:768–773
  32. Schmitt GJ, Meisenzahl EM, Dresel S, Tatsch K, Rossmuller B, Frodl T, et al. Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine. Journal of Psychopharmacology. 2002;16:200–206
  33. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975;188:1217–1219
  34. Shergill SS, Bullmore E, Simmons A, Murray RM, McGuire PK. Functional anatomy of auditory verbal imagery in schizophrenic patients with auditory hallucinations. American Journal of Psychiatry. 2000;157:1691–1693
  35. Shergill SS, Brammer MJ, Williams SCR, Murray RM, McGuire PK. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Archives of General Psychiatry. 2000;57:1033–1038
  36. Shergill SS, Brammer MJ, Fukuda R, Williams SCR, Murray RM, McGuire PK. Engagement of brain areas implicated in processing inner speech in people with auditory hallucinations. British Journal of Psychiatry. 2003;182:525–531
  37. Shergill SS, Brammer MJ, Amaro E, Williams SCR, Murray RM, McGuire PK. Temporal course of auditory hallucinations. British Journal of Psychiatry. 2004;185:516–517
  38. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature. 1995;378:176–179
  39. Slade P, Bentall R. Sensory Deception: A Scientific Analysis of Hallucination. London, England: Croom Helm; 2002;
  40. Suhara T, Okubo Y, Yasuno F, Sodo Y, Inoue M, Ichimiya T, et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Archives of General Psychiatry. 2002;59:25–30
  41. van Rossum JM. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In:  Brill H,  Cole JO,  Deniker P,  Hippius H,  Bradley PB editor. Proceedings of the Fifth Collegium Internationale Neuropsychopharmacologicum. Amsterdam: Excerpta Medica; 1967;p. 321–329
  42. Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Research Bulletin. 2001;56:495–507
  43. Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, Ichimiya T, et al. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. American Journal of Psychiatry. 2004;161:1016–1022

PII: S0925-4927(08)00176-5

doi: 10.1016/j.pscychresns.2008.11.001

Psychiatry Research: Neuroimaging
Volume 173, Issue 3 , Pages 183-189 , 30 September 2009

Article Tools

* Image Usage & Resolution